GlassScriptPhysician profile
Chudi N Adi
NPI 1992980015
$6,615.19
in general payments reported to CMS, 2019-2025
33 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $124 · 2021: $980 · 2022: $3,628 · 2023: $719 · 2024: $409 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.88 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,538.44 | 2022-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $568.89 | 2020-2024 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $513.68 | 2019-2024 | Injectafer |
| Vifor Pharma, INC. | $349.44 | 2019-2025 | Veltassa |
| Amgen INC. | $328.19 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $298.15 | 2021-2023 | Krystexxa |
| Nxstage Medical, INC. | $249.75 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $194.13 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $174.77 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $172.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $135.82 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $130.57 | 2019-2024 | Velphoro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.80 | 2021 | |
| Medtronic, INC. | $116.52 | 2022-2023 | Ellipsys Vascular Access System |
| Mozarc Medical US LLC | $93.62 | 2023 | Palindrome |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $77.64 | 2020-2025 | Ozempic, Rivfloza |
| Alexion Pharmaceuticals, INC. | $75.40 | 2021-2023 | Ultomiris |
| Vertex Pharmaceuticals Incorporated | $73.24 | 2022 | |
| Calliditas Therapeutics US INC. | $52.99 | 2023-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.82 | 2023 | Jynarque |
| Mallinckrodt Hospital Products INC. | $35.28 | 2024-2025 | Acthar |
| Amicus Therapeutics, INC. | $34.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.30 | 2019 | |
| W. L. Gore & Associates, INC. | $31.02 | 2025 | Gore Viabahn Endoprosthesis |
| Bard Peripheral Vascular, INC. | $29.84 | 2025 | Pristine |
| Apellis Pharmaceuticals, INC. | $27.15 | 2025 | |
| Ascendis Pharma Endocrinology INC | $22.47 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $20.63 | 2023 | Crysvita |
| Travere Therapeutics, INC. | $18.87 | 2022-2023 | |
| Cormedix INC. | $17.83 | 2025 | Defencath |
| Covidien LP | $14.56 | 2020 | |
| Chiesi USA, INC. | $13.20 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chudi Adi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.